Retatrutide HA 12mg

Description

Retatrutide is an investigational triple receptor agonist peptide that acts simultaneously on the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Developed by Eli Lilly, it represents a new class of multi-targeted metabolic peptides with powerful effects on weight regulation, glucose metabolism, and hepatic fat content. Its molecular structure is designed to optimize bioactivity across all three receptor systems, potentially addressing multiple facets of metabolic disease in a single therapeutic agent.

Benefits of Retatrutide peptide

As shown in multiple phase 2 trials, Retatrutide may promote significant and sustained weight loss, improve glycemic control in individuals with type 2 diabetes, and reduce hepatic steatosis in those with fatty liver disease. Clinical findings include:

• robust reductions in body weight, with up to 24.2% loss over 48 weeks

• substantial lowering of HbA1c levels in patients with type 2 diabetes

• reversal of prediabetes to normoglycemia in a majority of participants

• marked decrease in liver fat content among individuals with NAFLD

• improvements in cardiometabolic markers, including blood pressure and lipids

Its multi-receptor approach suggests that Retatrutide may be more effective than single-receptor agonists for treating complex metabolic disorders.

Retatrutide dosage and administration

In clinical studies, Retatrutide has been administered via subcutaneous injection in once-weekly regimens. Dosage is titrated gradually to mitigate gastrointestinal side effects and optimize tolerability. While precise dosing protocols vary by indication and trial design, the highest dose cohort in phase 2 studies received up to 12 mg weekly over a 48-week period.

This administration strategy aligns with existing GLP-1 and GIP receptor agonists, but with added activity at the glucagon receptor to promote energy expenditure and fat oxidation.

As this peptide is still in clinical development, its use should be limited strictly to research settings under professional supervision.

Indications and research applications

Retatrutide is currently being studied for its effects on several major metabolic and endocrine conditions, including:

• obesity and weight management

• type 2 diabetes mellitus

• nonalcoholic fatty liver disease (NAFLD)

• metabolic syndrome and insulin resistance

• prevention of progression from prediabetes to diabetes

Its multi-modal action profile—affecting appetite, energy use, fat metabolism, and glucose homeostasis—positions it as a potentially transformative therapy for chronic metabolic diseases.

Retatrutide side effects and safety considerations

Across trials, the most common adverse events reported were gastrointestinal in nature, including nausea, diarrhea, and constipation, particularly during dose escalation. These side effects are consistent with other GLP-1 based therapies. No severe adverse events related directly to the drug have been confirmed in published data. Nonetheless, long-term safety remains under investigation in phase 3 studies.

As a research peptide, Retatrutide should be handled with appropriate caution, and its administration restricted to professionals experienced with peptide therapeutics and metabolic research.

Buy Retatrutide at DN Research

For researchers investigating next-generation solutions for obesity, type 2 diabetes, or liver-related metabolic diseases, Retatrutide offers a promising platform. Visit DN Research to learn more and order high-purity Retatrutide for your research needs.

Legal disclaimer

This product is sold as a pure compound for research purposes only and is not meant for use as a dietary supplement. Please refer to our terms and conditions prior to purchase.

Safety information: Keep this product out of the reach of children. This material has limited research available and may result in adverse effects if improperly handled or consumed. This product is not a dietary supplement, but a pure substance, sold as a raw material. We attest exclusively to the quality, purity, and description of the materials we provide. This product is for use and handling only by persons with the knowledge and equipment to safely manage this material. You agree to indemnify DN Research for any adverse effects that may result from improper handling and/or use.

The articles and information on products that may be found on this website are provided exclusively for educational and research purposes. These items are not pharmaceuticals or medications, and the Food and Drug Administration has not approved them for the treatment or prevention of any disease or medical condition.